VKTX
The headline: still a science story, not a sales story
Viking Therapeutics just dropped its Q2 2026 results, and if you’re looking for product revenue fireworks, wrong tent. This is still very much a clinical-stage biotech story — aka the kind where the stock lives and dies by trial updates, timelines, and whether management sounds confident or vaguely caffeinated.
The good news? Viking says its Phase 3 VANQUISH 1 and 2 trials for subcutaneous VK2735 in obesity are fully enrolled and moving ahead. That’s the sort of phrase investors want to hear because in biotech, “fully enrolled” is basically the equivalent of finally getting everybody seated before the wedding starts.
The pipeline keeps inching forward
A few other breadcrumbs from the update matter:
- The oral Phase 3 VK2735 trial is expected to start in 4Q26
- Maintenance dosing data for VK2735 is expected in 3Q26
- A Phase 1 study of the amylin agonist VK3019 is already underway
That’s a decent amount of motion across the pipeline, and in biotech, motion is the product. No one’s buying a finished factory here — they’re buying the possibility that one of these programs turns into the next big obesity-market contender.
Cash matters, because biotech burns it like a vacation budget
Viking also ended the quarter with $502 million in cash. That’s important because drug development is expensive, and delays are not exactly rare in this business. A chunky cash pile buys time, and time buys optionality — which is basically biotech’s favorite currency after hope.
Big picture: this was a classic “the story is still intact” update. The stock will likely hinge less on the earnings math and more on whether Viking keeps stacking clinical milestones without tripping over the timeline.